The global point of care infectious disease testing market size is estimated to be USD 33.5 billion in 2021 and is expected to witness a CAGR of 1.6% during the forecast period. Developments in the point of care diagnostics (POC) equipment is a key driver for the growth of the global point of care infectious disease testing market. Additionally, changing healthcare reform to being patient- centred care and increase in demand for decentralized infectious disease testing are some of the other drivers propelling the market growth. Nevertheless, challenges related to the development of highly sensitive & accurate POC testing and high cost of point of care infectious disease testing treatment are expected to restrain the global market growth.
Based on disease type, the market is segmented into respiratory syncytial virus (RSV) POC, clostridium difficile POC, influenza/Flu POC, HPV POC, HBV POC, MRSA POC, HIV POC, pneumonia or streptococcus associated infections, HCV POC, HSV POC, TB & drug-resistant TB POC, and other POC. In 2021, the HIV POC segment accounted for the substantial revenue share with lucrative CAGR during the forecast period. This is attributed to the leading market players are investing in technologically advanced and accurate diagnosis devices are expected to improve penetration of these devices worldwide. Influenza/Flu POC segment projected to grow at a profitable CAGR during the forecast period. This is attributed to the major pharmaceutical and biotechnology companies investing in the point of care infectious disease testing market.
Based on end user, the market is segmented into home, clinics, hospitals, assisted living healthcare facilities, laboratories, and others. In 2021, the clinics segment accounted for the substantial revenue share with lucrative CAGR during the forecast period. This is attributed to the increasing adoption of these platforms and devices in clinics worldwide. Assisted living healthcare facilities segment projected to grow at a profitable CAGR during the forecast period. This is attributed to the increasing application of testing devices in this sector as a consequence of rise in demand by the geriatric population globally.
In 2021, North America accounted for the highest revenue share in the global market and is expected to maintain its dominance during the forecast period. This is attributed to the increase in the share of healthcare expenditure in the per capita income, presence of key players in the region, growth in initiatives from government, accessibility of technological advanced products in the region. Asia Pacific market is projected to exhibit the fastest CAGR over the forecast period owing to the intensely increase in burden of chronic infectious, growing government and corporate investment in healthcare sector, increasing travel tourism in the developing economies, are the major factors in this region.Competitor Insights Some of the key players in the point of care infectious disease testing market are Abbott Laboratories (U.S.); Bio-Rad Laboratories, Inc. (U.S.); Quest Diagnostics, Inc. (U.S.); Thermo Fisher Scientific, Inc. (U.S.); F.Hoffmann-La Roche Ltd (Switzerland); Danaher Corporation (U.S.); Siemens Healthineers AG (Germany); Sight Diagnostics Ltd (Israel); bioMérieux SA (France); Cardinal Health, Inc. (U.S.); Trinity Biotech (Ireland) Becton Dickinson Company (U.S.); and Becton Dickinson Company (U.S.). The leading players operating in the point of care infectious disease testing industry are adopting various strategies including R&D investments, adaption of advanced techniques, new technology launches, mergers & acquisitions, and regional expansions to capture a maximum revenue share.
This exhaustive research report focuses on market size and forecast at global, segmental, regional and country level along with key market trends and dynamics from 2021 to 2029. The point of care infectious disease testing market report is categorized into the following segments and subsegments:
By Disease Type
Based on disease type, the market is segmented into respiratory syncytial virus (RSV) POC, clostridium difficile POC, influenza/Flu POC, HPV POC, HBV POC, MRSA POC, HIV POC, pneumonia or streptococcus associated infections, HCV POC, HSV POC, TB & drug-resistant TB POC, and other POC. In 2021, the HIV POC segment accounted for the substantial revenue share with lucrative CAGR during the forecast period. This is attributed to the leading market players are investing in technologically advanced and accurate diagnosis devices are expected to improve penetration of these devices worldwide. Influenza/Flu POC segment projected to grow at a profitable CAGR during the forecast period. This is attributed to the major pharmaceutical and biotechnology companies investing in the point of care infectious disease testing market.
By End User
Based on end user, the market is segmented into home, clinics, hospitals, assisted living healthcare facilities, laboratories, and others. In 2021, the clinics segment accounted for the substantial revenue share with lucrative CAGR during the forecast period. This is attributed to the increasing adoption of these platforms and devices in clinics worldwide. Assisted living healthcare facilities segment projected to grow at a profitable CAGR during the forecast period. This is attributed to the increasing application of testing devices in this sector as a consequence of rise in demand by the geriatric population globally.
Regional Insights
In 2021, North America accounted for the highest revenue share in the global market and is expected to maintain its dominance during the forecast period. This is attributed to the increase in the share of healthcare expenditure in the per capita income, presence of key players in the region, growth in initiatives from government, accessibility of technological advanced products in the region. Asia Pacific market is projected to exhibit the fastest CAGR over the forecast period owing to the intensely increase in burden of chronic infectious, growing government and corporate investment in healthcare sector, increasing travel tourism in the developing economies, are the major factors in this region.Competitor Insights Some of the key players in the point of care infectious disease testing market are Abbott Laboratories (U.S.); Bio-Rad Laboratories, Inc. (U.S.); Quest Diagnostics, Inc. (U.S.); Thermo Fisher Scientific, Inc. (U.S.); F.Hoffmann-La Roche Ltd (Switzerland); Danaher Corporation (U.S.); Siemens Healthineers AG (Germany); Sight Diagnostics Ltd (Israel); bioMérieux SA (France); Cardinal Health, Inc. (U.S.); Trinity Biotech (Ireland) Becton Dickinson Company (U.S.); and Becton Dickinson Company (U.S.). The leading players operating in the point of care infectious disease testing industry are adopting various strategies including R&D investments, adaption of advanced techniques, new technology launches, mergers & acquisitions, and regional expansions to capture a maximum revenue share.
This exhaustive research report focuses on market size and forecast at global, segmental, regional and country level along with key market trends and dynamics from 2021 to 2029. The point of care infectious disease testing market report is categorized into the following segments and subsegments:
Point of Care Infectious Disease Testing Market, By Disease Type (Revenue, USD Billion, 2021 - 2029)
- Respiratory syncytial virus (RSV) POC
- Clostridium difficile POC
- Influenza/Flu POC
- HPV POC
- HBV POC
- MRSA POC
- HIV POC
- Pneumonia or Streptococcus associated infections
- HCV POC
- HSV POC
- TB and drug-resistant TB POC
- Other infectious disease POC
Point of Care Infectious Disease Testing Market, By End User (Revenue, USD Billion, 2021 - 2029)
- Home
- Clinics
- Hospitals
- Assisted Living Healthcare Facilities
- Laboratories
- Others
Point of Care Infectious Disease Testing Market, By Region (Revenue, USD Billion, 2021 - 2029)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- Saudi Arabia
- Rest of MEA
Table of Contents
1. Research Methodology
3. Executive Summary
4. Market Dynamics
5. Market Environment Analysis
6. COVID-19 Impact Analysis: Point of Care Infectious Disease Testing Market
7. Market Analysis by Type
8. Market Analysis by End User
9. Regional Market Analysis
10. North America Point of Care Infectious Disease Testing Market
11. Europe Point of Care Infectious Disease Testing Market
12. Asia Pacific Point of Care Infectious Disease Testing Market
13. Latin America Point of Care Infectious Disease Testing Market
14. MEA Point of Care Infectious Disease Testing Market
15. Competitor Analysis
16. Company Profiles
Companies Mentioned
A selection of companies mentioned in this report includes:
- Abbott Laboratories (U.S.)
- Bio-Rad Laboratories Inc. (U.S.)
- Quest Diagnostics Inc. (U.S.)
- Thermo Fisher Scientific Inc. (U.S.)
- F.Hoffmann-La Roche Ltd (Switzerland)
- Danaher Corporation (U.S.)
- Siemens Healthineers AG (Germany)
- Sight Diagnostics Ltd (Israel)
- bioMérieux SA (France)
- Cardinal Health Inc. (U.S.)
- Trinity Biotech (Ireland) Becton Dickinson Company (U.S.)
- Becton Dickinson Company (U.S.)
